Literature DB >> 8048744

Microheterogeneity of serum glycoproteins in alcoholics: is desialo-transferrin the marker of chronic alcohol drinking or alcoholic liver injury?

M Tsutsumi1, J S Wang, A Takada.   

Abstract

The appearance of desialo-transferrin (De-TF) in serum has been reported to be a biochemical marker of chronic alcoholism. However, conclusive evidence of whether De-TF is a marker for chronic alcohol drinking or for alcoholic liver disease (ALD) has not yet been obtained. Glycoproteins can be divided into two groups, a transferrin (TF) group and an alpha 1-acid glycoprotein (A1-AG) group, based on the characteristics of microheterogeneity (M-HTG) of each protein. In the present study, the appearance of M-HTG in serum TF and A1-AG in alcohol drinkers was compared. In 96 patients with ALD, M-HTG of TF was found in 66 patients (68.8%), and M-HTG of A1-AG was found in 61 patients (63.5%). In 20 patients with alcoholic pancreatitis, the detection rate of M-HTG of A1-AG was significantly higher than that of TF. In six patients with pancreatitis but not liver disease, M-HTG of TF was not detected. In 14 alcoholics without liver or pancreas disease, M-HTG of TF was not detected, whereas M-HTG of A1-AG was detected in 6 cases--a significant difference. The amount of alcohol consumed was not different in patients with and without liver disease. In non-ALD, M-HTG of both proteins was detected only in patients with decompensated liver cirrhosis. The detection rate of M-HTG in TF was significantly higher than in A1-AG. These results suggest that M-HTG of serum TF is a marker of ALD and that of serum A1-AG is a marker of chronic alcohol drinking.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8048744     DOI: 10.1111/j.1530-0277.1994.tb00031.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  8 in total

1.  Liver Galbeta1,4GlcNAc alpha2,6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates.

Authors:  Maokai Gong; Mamatha Garige; Kenneth Hirsch; M Raj Lakshman
Journal:  Metabolism       Date:  2007-09       Impact factor: 8.694

2.  New detection method after cellulose acetate membrane isoelectric focusing: activity staining for lactate dehydrogenase, detection for sugar chains using lectin and simple western blotting.

Authors:  S Iijima; M Kimura; K Shiba
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

3.  Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.

Authors:  Petra Darebna; Petr Novak; Radek Kucera; Ondrej Topolcan; Miloslav Sanda; Radoslav Goldman; Petr Pompach
Journal:  J Proteomics       Date:  2016-09-16       Impact factor: 4.044

4.  Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.

Authors:  Petr Pompach; Zuzana Brnakova; Miloslav Sanda; Jing Wu; Nathan Edwards; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

5.  Total and free serum sialic acid concentration in liver diseases.

Authors:  Ewa Gruszewska; Bogdan Cylwik; Anatol Panasiuk; Maciej Szmitkowski; Robert Flisiak; Lech Chrostek
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

6.  Protein and site specificity of fucosylation in liver-secreted glycoproteins.

Authors:  Petr Pompach; David J Ashline; Zuzana Brnakova; Julius Benicky; Miloslav Sanda; Radoslav Goldman
Journal:  J Proteome Res       Date:  2014-10-10       Impact factor: 4.466

7.  Exploiting lectin affinity chromatography in clinical diagnosis.

Authors:  P R Satish; A Surolia
Journal:  J Biochem Biophys Methods       Date:  2001-10-30

8.  Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium.

Authors:  Jianxiong Wu; Xietao Ye; Songhong Yang; Huan Yu; Lingyun Zhong; Qianfeng Gong
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.